These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 31820573

  • 21. [Factor IX assays in treated hemophilia B patients].
    Pouplard C, Jeanpierre E, Lasne D, Le Cam Duchez V, Eschwege V, Flaujac C, Galinat H, Harzallah I, Proulle V, Smahi M, Sobas F, Ternisien C, Toulon P, Voisin S, Nougier C, groupe d’études de la biologie des maladies hémorragiques du Groupe français d’études de l’hémostase et la thrombose.
    Ann Biol Clin (Paris); 2019 Feb 01; 77(1):41-52. PubMed ID: 30799297
    [Abstract] [Full Text] [Related]

  • 22. Overestimation of N-glycoPEGylated factor IX activity in a one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX.
    Rosén P, Rosén S, Ezban M, Persson E.
    J Thromb Haemost; 2016 Jul 01; 14(7):1420-7. PubMed ID: 27169618
    [Abstract] [Full Text] [Related]

  • 23. Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors.
    Pochopien M, Tytuła A, Toumi M, Falk A, Martone N, Hakimi Z, Eriksson D.
    Adv Ther; 2024 Jun 01; 41(6):2307-2323. PubMed ID: 38652439
    [Abstract] [Full Text] [Related]

  • 24. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study.
    Powell JS, Apte S, Chambost H, Hermans C, Jackson S, Josephson NC, Mahlangu JN, Ozelo MC, Peerlinck K, Pasi J, Perry D, Ragni MV, Wang X, Jiang H, Li S, Cristiano LM, Innes A, Nugent K, Brennan A, Luk A, Allen G, Pierce GF, Robinson B.
    Br J Haematol; 2015 Jan 01; 168(1):124-34. PubMed ID: 25208598
    [Abstract] [Full Text] [Related]

  • 25. Evaluation of the toxicology, pharmacokinetics, and local tolerance of recombinant factor IX Fc fusion protein in animals.
    Dumont JA, Loveday KS, Light DR, Pierce GF, Jiang H.
    Thromb Res; 2015 Aug 01; 136(2):371-8. PubMed ID: 25840744
    [Abstract] [Full Text] [Related]

  • 26. Eftrenonacog Alfa: A Review in Haemophilia B.
    Hoy SM.
    Drugs; 2017 Jul 01; 77(11):1235-1246. PubMed ID: 28646426
    [Abstract] [Full Text] [Related]

  • 27. Transplacental delivery of factor IX Fc-fusion protein ameliorates bleeding phenotype of newborn hemophilia B mice.
    Sakurai F, Iizuka S, Tsukamoto T, Shiota A, Shimizu K, Ohashi K, Mizuguchi H.
    J Control Release; 2024 Oct 01; 374():415-424. PubMed ID: 39181162
    [Abstract] [Full Text] [Related]

  • 28. Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX-Fc fusion protein: A randomized trial.
    Escuriola Ettingshausen C, Hegemann I, Simpson ML, Cuker A, Kulkarni R, Pruthi RK, Garly ML, Meldgaard RM, Persson P, Klamroth R.
    Res Pract Thromb Haemost; 2019 Apr 01; 3(2):268-276. PubMed ID: 31011711
    [Abstract] [Full Text] [Related]

  • 29. Real-world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow-up in a national adult cohort.
    O'Donovan M, Bergin C, Quinn E, Singleton E, Roche S, Benson J, Bird R, Byrne M, Duggan C, Gilmore R, Ryan K, O'Donnell JS, O'Connell NM.
    Haemophilia; 2021 Jul 01; 27(4):618-625. PubMed ID: 33939224
    [Abstract] [Full Text] [Related]

  • 30. Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias.
    Mancuso ME, Mannucci PM.
    Drug Des Devel Ther; 2014 Jul 01; 8():365-71. PubMed ID: 24729686
    [Abstract] [Full Text] [Related]

  • 31. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.
    Shapiro AD, Ragni MV, Valentino LA, Key NS, Josephson NC, Powell JS, Cheng G, Thompson AR, Goyal J, Tubridy KL, Peters RT, Dumont JA, Euwart D, Li L, Hallén B, Gozzi P, Bitonti AJ, Jiang H, Luk A, Pierce GF.
    Blood; 2012 Jan 19; 119(3):666-72. PubMed ID: 22110246
    [Abstract] [Full Text] [Related]

  • 32. Discovery of An Orally Effective Factor IX-Transferrin Fusion Protein for Hemophilia B.
    Xie C, Wang Z, Su Y, Wang J, Shen WC.
    Int J Mol Sci; 2019 Dec 18; 21(1):. PubMed ID: 31861459
    [Abstract] [Full Text] [Related]

  • 33. In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates.
    Preijers T, Bukkems L, van Spengler M, Leebeek F, Cnossen M, Mathôt R.
    Eur J Clin Pharmacol; 2021 Aug 18; 77(8):1193-1200. PubMed ID: 33624121
    [Abstract] [Full Text] [Related]

  • 34. Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP.
    Davis J, Yan S, Matsushita T, Alberio L, Bassett P, Santagostino E.
    J Med Econ; 2019 Oct 18; 22(10):1014-1021. PubMed ID: 31094591
    [Abstract] [Full Text] [Related]

  • 35. In vivo intranasal delivery of coagulation factor IX: a proof-of-concept study.
    Fieux M, Rovera R, Coiffier C, Colomb E, Enjolras N, Béquignon E, Monge C, Le Quellec S.
    J Thromb Haemost; 2023 Nov 18; 21(11):3117-3123. PubMed ID: 37633640
    [Abstract] [Full Text] [Related]

  • 36. Matching-Adjusted Indirect Comparison of Recombinant Factor IX Albumin Fusion Protein Versus Recombinant Factor IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia B.
    Guillet B, Yan S, Hooper B, Drelich D, Steenkamp J, Tomic R, Mancuso ME.
    Adv Ther; 2024 Feb 18; 41(2):649-658. PubMed ID: 38070040
    [Abstract] [Full Text] [Related]

  • 37. Conformational comparability of factor IX-Fc fusion protein, factor IX, and purified Fc fragment in the absence and presence of calcium.
    Houde D, Berkowitz SA.
    J Pharm Sci; 2012 May 18; 101(5):1688-700. PubMed ID: 22271461
    [Abstract] [Full Text] [Related]

  • 38. Prophylaxis with recombinant factor IX Fc fusion protein reduces the risk of bleeding and delays time to first spontaneous bleed event in previously untreated patients with haemophilia B: A post hoc analysis of the PUPs B-LONG study.
    Nolan B, Recht M, Rendo P, Falk A, Foster M, Casiano S, Rauch A, Shapiro A.
    Eur J Haematol; 2024 Oct 18; 113(4):485-492. PubMed ID: 38922990
    [Abstract] [Full Text] [Related]

  • 39. Performance of factor IX extended half-life product measurements in external quality control assessment programs.
    Nederlof A, Kitchen S, Meijer P, Cnossen M, Ali Pour N, Kershaw G, Jennings I, Walker I, de Maat MPM.
    J Thromb Haemost; 2020 Aug 18; 18(8):1874-1883. PubMed ID: 32311825
    [Abstract] [Full Text] [Related]

  • 40. Eftrenonacog Alfa: A Review in Haemophilia B.
    Lamb YN, Hoy SM.
    Drugs; 2023 Jun 18; 83(9):807-818. PubMed ID: 37081241
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.